Sanofi (NASDAQ:SNY) Shares Acquired by Verdence Capital Advisors LLC

Verdence Capital Advisors LLC increased its position in shares of Sanofi (NASDAQ:SNY) by 2.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 30,523 shares of the company’s stock after acquiring an additional 764 shares during the quarter. Verdence Capital Advisors LLC’s holdings in Sanofi were worth $1,759,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Northwest Investment Counselors LLC acquired a new stake in Sanofi during the third quarter worth $29,000. POM Investment Strategies LLC acquired a new stake in shares of Sanofi during the 2nd quarter worth about $25,000. Concord Wealth Partners increased its position in shares of Sanofi by 157.8% during the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after purchasing an additional 363 shares during the last quarter. Arrow Financial Corp purchased a new stake in Sanofi in the 2nd quarter valued at about $35,000. Finally, Fortitude Family Office LLC boosted its stake in Sanofi by 708.6% during the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after buying an additional 659 shares during the period. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Sanofi Trading Down 0.8 %

NASDAQ SNY opened at $51.32 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The firm has a market cap of $130.24 billion, a price-to-earnings ratio of 26.18, a PEG ratio of 1.31 and a beta of 0.61. The firm has a 50 day simple moving average of $55.49 and a 200-day simple moving average of $52.20. Sanofi has a one year low of $45.13 and a one year high of $58.97.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating the consensus estimate of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The company had revenue of $13.44 billion during the quarter, compared to analysts’ expectations of $16.59 billion. During the same quarter last year, the company posted $2.55 EPS. The firm’s revenue was up 12.3% compared to the same quarter last year. Equities research analysts anticipate that Sanofi will post 4.27 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Thursday. Citigroup raised Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Finally, Argus raised their price target on Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Two investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Sanofi currently has an average rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.